IE47062B1 - Method of facilitating genetic exchange in streptomyces and nocardia by protoplast fusion - Google Patents
Method of facilitating genetic exchange in streptomyces and nocardia by protoplast fusionInfo
- Publication number
- IE47062B1 IE47062B1 IE1318/78A IE131878A IE47062B1 IE 47062 B1 IE47062 B1 IE 47062B1 IE 1318/78 A IE1318/78 A IE 1318/78A IE 131878 A IE131878 A IE 131878A IE 47062 B1 IE47062 B1 IE 47062B1
- Authority
- IE
- Ireland
- Prior art keywords
- genetic exchange
- strains
- genetic
- exchange
- var
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 93
- 210000001938 protoplast Anatomy 0.000 title claims abstract description 61
- 241000187747 Streptomyces Species 0.000 title claims abstract description 28
- 230000004927 fusion Effects 0.000 title claims abstract description 22
- 241000187654 Nocardia Species 0.000 title claims abstract description 21
- 230000030414 genetic transfer Effects 0.000 title claims description 69
- 230000008569 process Effects 0.000 claims abstract description 69
- 210000004027 cell Anatomy 0.000 claims description 24
- 241000894007 species Species 0.000 claims description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- 241000187438 Streptomyces fradiae Species 0.000 claims description 16
- 102000016943 Muramidase Human genes 0.000 claims description 12
- 108010014251 Muramidase Proteins 0.000 claims description 12
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 12
- 241000187391 Streptomyces hygroscopicus Species 0.000 claims description 12
- 229960000274 lysozyme Drugs 0.000 claims description 11
- 235000010335 lysozyme Nutrition 0.000 claims description 11
- 239000004325 lysozyme Substances 0.000 claims description 11
- 230000002068 genetic effect Effects 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 241000063122 Streptacidiphilus griseus Species 0.000 claims description 9
- 241000187759 Streptomyces albus Species 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- 241000187434 Streptomyces cinnamonensis Species 0.000 claims description 8
- 241000186984 Kitasatospora aureofaciens Species 0.000 claims description 6
- 241000186992 Streptomyces bikiniensis Species 0.000 claims description 6
- 210000002421 cell wall Anatomy 0.000 claims description 6
- 241000187178 Streptoalloteichus tenebrarius Species 0.000 claims description 5
- 241000187760 Streptomyces albogriseolus Species 0.000 claims description 5
- 241000958233 Streptomyces candidus Species 0.000 claims description 5
- 241000933209 Streptomyces eurocidicus Species 0.000 claims description 5
- 241001312733 Streptomyces griseofuscus Species 0.000 claims description 5
- 241001147855 Streptomyces cattleya Species 0.000 claims description 4
- 241000187433 Streptomyces clavuligerus Species 0.000 claims description 4
- 241000970271 Streptomyces crystallinus Species 0.000 claims description 4
- 241000971005 Streptomyces fungicidicus Species 0.000 claims description 4
- 241001494960 Streptomyces griseoflavus Species 0.000 claims description 4
- 241000810787 Streptomyces kasugaspinus Species 0.000 claims description 4
- 241001662084 Streptomyces lasaliensis Species 0.000 claims description 4
- 241000187389 Streptomyces lavendulae Species 0.000 claims description 4
- 241000187395 Streptomyces microflavus Species 0.000 claims description 4
- 241000946831 Streptomyces narbonensis Species 0.000 claims description 4
- 241000946849 Streptomyces noboritoensis Species 0.000 claims description 4
- 241000218589 Streptomyces olivaceus Species 0.000 claims description 4
- 241000187419 Streptomyces rimosus Species 0.000 claims description 4
- 241000187418 Streptomyces rochei Species 0.000 claims description 4
- 241000970854 Streptomyces violaceusniger Species 0.000 claims description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 4
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 4
- 241000187390 Amycolatopsis lactamdurans Species 0.000 claims description 3
- 241000936887 Saccharothrix mutabilis subsp. capreolus Species 0.000 claims description 3
- 240000003801 Sigesbeckia orientalis Species 0.000 claims description 3
- 241000187758 Streptomyces ambofaciens Species 0.000 claims description 3
- 241000970227 Streptomyces fimbriatus Species 0.000 claims description 3
- 241000187216 Streptomyces halstedii Species 0.000 claims description 3
- 241000187132 Streptomyces kanamyceticus Species 0.000 claims description 3
- 241000187214 Streptomyces kasugaensis Species 0.000 claims description 3
- 241000394406 Streptomyces kitasatoensis Species 0.000 claims description 3
- 241000187399 Streptomyces lincolnensis Species 0.000 claims description 3
- 241001600133 Streptomyces ribosidificus Species 0.000 claims description 3
- 230000003698 anagen phase Effects 0.000 claims description 3
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000001172 regenerating effect Effects 0.000 claims description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 3
- 239000002132 β-lactam antibiotic Substances 0.000 claims description 3
- 229940124586 β-lactam antibiotics Drugs 0.000 claims description 3
- 241001430311 Amycolatopsis lurida Species 0.000 claims description 2
- 240000002900 Arthrospira platensis Species 0.000 claims description 2
- 241000520858 Nocardia uniformis Species 0.000 claims description 2
- 241000133261 Scabropezia flavovirens Species 0.000 claims description 2
- 240000009225 Stachytarpheta mutabilis Species 0.000 claims description 2
- 241000187220 Streptomyces albireticuli Species 0.000 claims description 2
- 241000186988 Streptomyces antibioticus Species 0.000 claims description 2
- 241000958254 Streptomyces argenteolus Species 0.000 claims description 2
- 241000970286 Streptomyces atrofaciens Species 0.000 claims description 2
- 241001467538 Streptomyces bluensis Species 0.000 claims description 2
- 241001509463 Streptomyces caelestis Species 0.000 claims description 2
- 241000936796 Streptomyces catenulae Species 0.000 claims description 2
- 241000970248 Streptomyces cirratus Species 0.000 claims description 2
- 241000187432 Streptomyces coelicolor Species 0.000 claims description 2
- 241000970256 Streptomyces djakartensis Species 0.000 claims description 2
- 241000811239 Streptomyces erythrochromogenes Species 0.000 claims description 2
- 241000142901 Streptomyces eurythermus Species 0.000 claims description 2
- 241000520732 Streptomyces felleus Species 0.000 claims description 2
- 241000958221 Streptomyces flaveolus Species 0.000 claims description 2
- 241000933812 Streptomyces flaveus Species 0.000 claims description 2
- 241000936697 Streptomyces fulvoviridis Species 0.000 claims description 2
- 241000913723 Streptomyces heteromorphus Species 0.000 claims description 2
- 241000784557 Streptomyces lividus Species 0.000 claims description 2
- 241000970926 Streptomyces longwoodensis Species 0.000 claims description 2
- 241000970921 Streptomyces macrosporeus Species 0.000 claims description 2
- 241000187233 Streptomyces mycarofaciens Species 0.000 claims description 2
- 241000542929 Streptomyces netropsis Species 0.000 claims description 2
- 241000970901 Streptomyces olivoreticuli Species 0.000 claims description 2
- 241000913724 Streptomyces panayensis Species 0.000 claims description 2
- 241000970898 Streptomyces rameus Species 0.000 claims description 2
- 241000334075 Streptomyces rimofaciens Species 0.000 claims description 2
- 241000320554 Streptomyces rimosus subsp. paromomycinus Species 0.000 claims description 2
- 241000747254 Streptomyces rochei subsp. volubilis Species 0.000 claims description 2
- 241000946750 Streptomyces sioyaensis Species 0.000 claims description 2
- 241000970875 Streptomyces spectabilis Species 0.000 claims description 2
- 241000810785 Streptomyces spinichromogenes Species 0.000 claims description 2
- 241001600136 Streptomyces thermotolerans Species 0.000 claims description 2
- 241000531819 Streptomyces venezuelae Species 0.000 claims description 2
- 241000187191 Streptomyces viridochromogenes Species 0.000 claims description 2
- 241001248020 Streptomyces wadayamensis Species 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 241000936863 Streptomyces albofaciens Species 0.000 claims 1
- 241000186990 Streptomyces cacaoi Species 0.000 claims 1
- 241000970242 Streptomyces chrestomyceticus Species 0.000 claims 1
- 241000933213 Streptomyces cinerochromogenes Species 0.000 claims 1
- 241001467541 Streptomyces galbus Species 0.000 claims 1
- 241000187435 Streptomyces griseolus Species 0.000 claims 1
- 241001468228 Streptomyces mashuensis Species 0.000 claims 1
- 241000187134 Streptomyces olivochromogenes Species 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000002460 polyether antibiotic agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 238000011161 development Methods 0.000 abstract description 3
- 230000004888 barrier function Effects 0.000 abstract description 2
- 230000002255 enzymatic effect Effects 0.000 abstract description 2
- 210000004754 hybrid cell Anatomy 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 31
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 16
- 230000003115 biocidal effect Effects 0.000 description 15
- 230000006798 recombination Effects 0.000 description 8
- 229960005322 streptomycin Drugs 0.000 description 8
- 244000005700 microbiome Species 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- 229930188120 Carbomycin Natural products 0.000 description 6
- FQVHOULQCKDUCY-OGHXVOSASA-N [(2s,3s,4r,6s)-6-[(2r,3s,4r,5r,6s)-6-[[(1s,3r,7r,8s,9s,10r,12r,14e,16s)-7-acetyloxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimeth Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@H]1[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@@H]2O[C@H]2C[C@@H](C)OC(=O)C[C@H]([C@@H]1OC)OC(C)=O)[C@H]1C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1 FQVHOULQCKDUCY-OGHXVOSASA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229950005779 carbomycin Drugs 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000001974 tryptic soy broth Substances 0.000 description 6
- 108010050327 trypticase-soy broth Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- UZQBOFAUUTZOQE-VSLWXVDYSA-N pikromycin Chemical compound C[C@H]1C[C@@H](C)C(=O)\C=C\[C@@](O)(C)[C@@H](CC)OC(=O)[C@H](C)C(=O)[C@H](C)[C@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1 UZQBOFAUUTZOQE-VSLWXVDYSA-N 0.000 description 5
- 229960000268 spectinomycin Drugs 0.000 description 5
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 5
- BYWWNDLILWPPJP-REXWONOSSA-N Albocycline Chemical compound CO[C@H]1\C=C\[C@@](C)(O)\C=C\C(=O)O[C@H](C)[C@@H](C)CC\C=C1/C BYWWNDLILWPPJP-REXWONOSSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 4
- 239000004182 Tylosin Substances 0.000 description 4
- 229930194936 Tylosin Natural products 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000013011 mating Effects 0.000 description 4
- 229960001914 paromomycin Drugs 0.000 description 4
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 4
- 229960004059 tylosin Drugs 0.000 description 4
- 235000019375 tylosin Nutrition 0.000 description 4
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 4
- BYWWNDLILWPPJP-UHFFFAOYSA-N Albocycline Natural products COC1C=CC(C)(O)C=CC(=O)OC(C)C(C)CCC=C1C BYWWNDLILWPPJP-UHFFFAOYSA-N 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 239000008118 PEG 6000 Substances 0.000 description 3
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 3
- 229960004144 josamycin Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- OJCKRNPLOZHAOU-RSXXJMTFSA-N (1r,2r)-2-[(2s,4e,6e,8r,9s,11r,13s,15s,16s)-7-cyano-8,16-dihydroxy-9,11,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6-dien-2-yl]cyclopentane-1-carboxylic acid Chemical compound O1C(=O)C[C@H](O)[C@@H](C)C[C@@H](C)C[C@@H](C)C[C@H](C)[C@@H](O)\C(C#N)=C\C=C\C[C@H]1[C@H]1[C@H](C(O)=O)CCC1 OJCKRNPLOZHAOU-RSXXJMTFSA-N 0.000 description 2
- BKZOUCVNTCLNFF-IGXZVFLKSA-N (2s)-2-[(2r,3r,4s,5r,6s)-2-hydroxy-6-[(1s)-1-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-[(2r,3s,4r,5r)-5-[(2s,3s,4s,5r,6s)-6-hydroxy-4-methoxy-3,5,6-trimethyloxan-2-yl]-4-methoxy-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-7-methoxy-2,8-dimethyl-1,10-dioxaspiro[4.5]dec Chemical compound O([C@@H]1[C@@H]2O[C@H]([C@@H](C)[C@H]2OC)[C@@]2(C)O[C@H](CC2)[C@@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](OC)C3)[C@@H](C)[C@@H]3[C@@H]([C@H](OC)[C@@H](C)[C@](O)([C@H](C)C(O)=O)O3)C)CC2)[C@](C)(O)[C@H](C)[C@@H](OC)[C@@H]1C BKZOUCVNTCLNFF-IGXZVFLKSA-N 0.000 description 2
- QDAVFUSCCPXZTE-VMXQISHHSA-N (4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-[(2r,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-7 Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCO)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 QDAVFUSCCPXZTE-VMXQISHHSA-N 0.000 description 2
- DIKYHBWGIUNGIW-UHFFFAOYSA-N 2-[2,4-dihydroxy-6-[1-[2-[5-[5-(6-hydroxy-4-methoxy-3,5,6-trimethyloxan-2-yl)oxolan-2-yl]-5-methyloxolan-2-yl]-7-methoxy-2,6-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]ethyl]-5-(5-methoxy-6-methyloxan-2-yl)oxy-3,5-dimethyloxan-2-yl]propanoic acid Chemical compound O1C(C)C(OC)CCC1OC1(C)C(C(C)C2OC3(OC(C)(CC3)C3OC(C)(CC3)C3OC(CC3)C3C(C(OC)C(C)C(C)(O)O3)C)C(C)C(OC)C2)OC(O)(C(C)C(O)=O)C(C)C1O DIKYHBWGIUNGIW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- OJCKRNPLOZHAOU-BNXNOGCYSA-N Borrelidin Natural products CC1CC(C)CC(C)C(O)C(=C/C=C/CC(OC(=O)CC(O)C(C)C1)C2CCCC2C(=O)O)C#N OJCKRNPLOZHAOU-BNXNOGCYSA-N 0.000 description 2
- ATDILMLBOZKFGI-JUTMVFGESA-N Lankacidin C Chemical compound C1[C@H](O)\C=C\C(\C)=C\C[C@H](O)\C=C\C(\C)=C\[C@@H](NC(=O)C(C)=O)[C@@]2(C)C(=O)[C@H](C)[C@@H]1OC2=O ATDILMLBOZKFGI-JUTMVFGESA-N 0.000 description 2
- KTQFYFLZDLTLAH-UHFFFAOYSA-N Lysocellin Natural products CCC(O)C1(CC)CC(C)C(O)(O1)C2(C)CC(C)C(O2)C(CC)C(=O)C(C)C(O)C(C)C3OC(O)(CC(=O)O)C(C)CC3C KTQFYFLZDLTLAH-UHFFFAOYSA-N 0.000 description 2
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 description 2
- 239000004104 Oleandomycin Substances 0.000 description 2
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 108010081391 Ristocetin Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- -1 aminoglycoside Substances 0.000 description 2
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- LXWBXEWUSAABOA-VXSYNFHWSA-N cephamycin C Chemical compound S1CC(COC(N)=O)=C(C(O)=O)N2C(=O)[C@@](OC)(NC(=O)CCC[C@@H](N)C(O)=O)[C@H]21 LXWBXEWUSAABOA-VXSYNFHWSA-N 0.000 description 2
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229930184823 lankacidin Natural products 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KTQFYFLZDLTLAH-DESDHLEASA-N lysocellin Chemical compound O1[C@]([C@@H](O)CC)(CC)C[C@@H](C)[C@]1(O)[C@@]1(C)O[C@H]([C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CC(O)=O)O2)C)[C@@H](C)C1 KTQFYFLZDLTLAH-DESDHLEASA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960002757 midecamycin Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000019367 oleandomycin Nutrition 0.000 description 2
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 2
- 229960002351 oleandomycin Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000002135 phase contrast microscopy Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229950010526 relomycin Drugs 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RZLRMVZBGPHYJA-XXJPCBNGSA-N (1s,2e,5s,8s,9s,10e,14r,15r,16s)-5-hydroxy-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-8-[(2s,3r,4s,6r)-3-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5,9,14-trimethyl-13,17-dioxabicyclo[14.1.0]heptadeca-2,10-diene-4,12-dione Chemical compound O[C@@H]1[C@@H](OC)C[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)/C=C/C(=O)O[C@H](C)[C@@H](CO[C@H]2[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O2)OC)[C@@H]2O[C@H]2/C=C/C(=O)[C@@](C)(O)CC1 RZLRMVZBGPHYJA-XXJPCBNGSA-N 0.000 description 1
- ZITSQIZMRMDQLE-SJSJOXFOSA-N (2R)-2-[(2R,3S,6R)-6-[[(2S,4R,5R,6R,7R,9R)-2-[(2R,5S)-5-[(2R,3S,5R)-5-[(2S,3S,5R,6S)-6-hydroxy-3,5,6-trimethyloxan-2-yl]-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-7-methoxy-2,4,6-trimethyl-1,10-dioxaspiro[4.5]decan-9-yl]methyl]-3-methyloxan-2-yl]propanoic acid Chemical compound CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@@H](O2)[C@@H](C)C(O)=O)O[C@]2(O[C@@](C)(C[C@H]2C)[C@H]2CC[C@](C)(O2)[C@@H]2O[C@H](C[C@@H]2C)[C@H]2O[C@](C)(O)[C@H](C)C[C@@H]2C)[C@@H]1C ZITSQIZMRMDQLE-SJSJOXFOSA-N 0.000 description 1
- JARYYMUOCXVXNK-FCFLIOTHSA-N (2S,3R,4S,5S,6R)-2-[(1R,2R,3S,4S,6R)-2,3-dihydroxy-6-(hydroxymethyl)-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical class OC[C@H]1C[C@H](N[C@H]2C=C(CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JARYYMUOCXVXNK-FCFLIOTHSA-N 0.000 description 1
- ZNBNBTIDJSKEAM-NISBWGIBSA-N (2s,3r,4r)-4-[(2s,5r,7s,8r,9s)-7-hydroxy-2-[(2r,5s)-5-[(2r,3s,5r)-5-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-2-methyl-3-propanoyloxypentanoic a Chemical compound C1[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC(=O)CC)[C@H](C)C(O)=O)O[C@]11O[C@](C)([C@@H]2O[C@@](C)(CC2)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)CC1 ZNBNBTIDJSKEAM-NISBWGIBSA-N 0.000 description 1
- GRRNUXAQVGOGFE-SVNOMHMPSA-N (3'r,3as,4s,4's,5'r,6r,6'r,7s,7as)-4-[(1s,2r,3s,5r,6s)-3-amino-2,6-dihydroxy-5-(methylamino)cyclohexyl]oxy-6'-[(1s)-1-amino-2-hydroxyethyl]-6-(hydroxymethyl)spiro[4,6,7,7a-tetrahydro-3ah-[1,3]dioxolo[4,5-c]pyran-2,2'-oxane]-3',4',5',7-tetrol Chemical compound O[C@H]1[C@H](NC)C[C@H](N)[C@@H](O)[C@@H]1O[C@H]1[C@H]2OC3([C@@H]([C@@H](O)[C@@H](O)[C@@H]([C@@H](N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-SVNOMHMPSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- KZXDKUWSAVUSKI-JQIJEIRASA-N 2-[(14e)-9-[5-(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-3-ethyl-7-hydroxy-2-[(5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl)oxymethyl]-8,12,16-trimethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl]acetaldehy Chemical compound O=CCC1CC(C)C(=O)\C=C\C2(C)OC2C(COC2C(C(OC)C(O)C(C)O2)OC)C(CC)OC(=O)CC(O)C(C)C1OC(OC1C)CC(N(C)C)C1OC1CC(C)(O)C(O)C(C)O1 KZXDKUWSAVUSKI-JQIJEIRASA-N 0.000 description 1
- QTUJBJINYXOXOU-VVPCINPTSA-N 5-Ribosylparomamine Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](CO)O1)O)O)N)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1N QTUJBJINYXOXOU-VVPCINPTSA-N 0.000 description 1
- UNFWWIHTNXNPBV-UHFFFAOYSA-N Actinospectacin Natural products O1C2C(O)C(NC)C(O)C(NC)C2OC2(O)C1OC(C)CC2=O UNFWWIHTNXNPBV-UHFFFAOYSA-N 0.000 description 1
- 229930191212 Aldgamycin Natural products 0.000 description 1
- YERYDTDNBAJCQO-UHFFFAOYSA-N Angolamycin Natural products CCC1OC(=O)CC(O)C(C)C(OCCC(C(OCCC(C)(O)C(O)C(C)OC)C(C)OC)N(C)C)C(CC=O)CC(C)C(=O)C=CC2(C)OC2C1COC3OC(C)C(O)C(OC)C3OC YERYDTDNBAJCQO-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000004184 Avoparcin Substances 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101100290837 Bacillus subtilis (strain 168) metAA gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- AGMXVTRKEHGDRH-CSKMKTBNSA-N Cephamycin-A Natural products COC(=Cc1ccc(OS(=O)(=O)O)cc1)C(=O)OCC2=C(N3[C@H](SC2)[C@@](NC(=O)CCC[C@H](N)C(=O)O)(OC)C3=O)C(=O)O AGMXVTRKEHGDRH-CSKMKTBNSA-N 0.000 description 1
- LXWBXEWUSAABOA-UHFFFAOYSA-N Cephamycin-C Natural products S1CC(COC(N)=O)=C(C(O)=O)N2C(=O)C(OC)(NC(=O)CCCC(N)C(O)=O)C21 LXWBXEWUSAABOA-UHFFFAOYSA-N 0.000 description 1
- KLGADJPDTCIJLO-LJUCOGSUSA-N Chalcomycin Chemical compound O[C@@H]1[C@@H](OC)C[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)/C=C/C(=O)O[C@H](C)[C@@H](CO[C@H]2[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O2)OC)[C@H]2O[C@@H]2/C=C/C(=O)[C@@](C)(O)C[C@@H]1C KLGADJPDTCIJLO-LJUCOGSUSA-N 0.000 description 1
- 229930186967 Cineromycin Natural products 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- RZLRMVZBGPHYJA-UHFFFAOYSA-N Cynanformoside B Natural products OC1C(OC)CC(C)OC1OC1C(C)C=CC(=O)OC(C)C(COC2C(C(OC)C(O)C(C)O2)OC)C2OC2C=CC(=O)C(C)(O)CC1 RZLRMVZBGPHYJA-UHFFFAOYSA-N 0.000 description 1
- 229930192258 Deltamycin Natural products 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000331993 Erythraeus Species 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 229930191122 Foromacidin Natural products 0.000 description 1
- ZITSQIZMRMDQLE-UHFFFAOYSA-N Grisorixin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(C)(O)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 ZITSQIZMRMDQLE-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 229930193789 Kujimycin Natural products 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CFMSCYSETWZXRS-UHFFFAOYSA-N Lactenocin Natural products O=CCC1CC(C)C(=O)C=CC(C)=CC(COC2C(C(O)C(O)C(C)O2)OC)C(CC)OC(=O)CC(O)C(C)C1OC1OC(C)C(O)C(N(C)C)C1O CFMSCYSETWZXRS-UHFFFAOYSA-N 0.000 description 1
- RWWSBGHRGAQGJE-UHFFFAOYSA-N Laidlomycin Natural products CC(C(CCC(=O)O)C(C)C(=O)O)C1OC2(CCC(C)(O2)C3CCC(C)(O3)C4OC(CC4C)C5OC(O)(CO)C(C)CC5C)CC(O)C1C RWWSBGHRGAQGJE-UHFFFAOYSA-N 0.000 description 1
- 229930182504 Lasalocid Natural products 0.000 description 1
- IEMDOFXTVAPVLX-YWQHLDGFSA-N Leucomycin A1 Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 IEMDOFXTVAPVLX-YWQHLDGFSA-N 0.000 description 1
- 229930183998 Lividomycin Natural products 0.000 description 1
- BKZOUCVNTCLNFF-UHFFFAOYSA-N Lonomycin Natural products COC1C(C)C(C2(C)OC(CC2)C2(C)OC3(OC(C(C)C(OC)C3)C(C)C3C(C(OC)C(C)C(O)(C(C)C(O)=O)O3)C)CC2)OC1C1OC(C)(O)C(C)C(OC)C1C BKZOUCVNTCLNFF-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 101710200784 Major structural subunit of bundle-forming pilus Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930184158 Maridomycin Natural products 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- VHKXXVVRRDYCIK-CWCPJSEDSA-N Narasin Chemical compound C[C@H]1C[C@H](C)[C@H]([C@@H](CC)C(O)=O)O[C@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 VHKXXVVRRDYCIK-CWCPJSEDSA-N 0.000 description 1
- VHKXXVVRRDYCIK-UHFFFAOYSA-N Narasin Natural products CC1CC(C)C(C(CC)C(O)=O)OC1C(C)C(O)C(C)C(=O)C(CC)C1C(C)CC(C)C2(C=CC(O)C3(OC(C)(CC3)C3OC(C)C(O)(CC)CC3)O2)O1 VHKXXVVRRDYCIK-UHFFFAOYSA-N 0.000 description 1
- VXVAFQMBYKUOIZ-UHFFFAOYSA-N Neutramycin Natural products COC(=O)C=CC#CC#CCO VXVAFQMBYKUOIZ-UHFFFAOYSA-N 0.000 description 1
- REPPNUPKOJKPSP-ZZNWINOMSA-N Niddamycin Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\C(=O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)C(C)C)[C@](C)(O)C2)[C@@H](C)O1 REPPNUPKOJKPSP-ZZNWINOMSA-N 0.000 description 1
- PXUIVECFRJIQIG-UHFFFAOYSA-N Niddamycin Natural products COC1C(CC(CC(C)C(=O)C=CC=C/CC(C)OC(=O)CC1OC(=O)C)C=O)OC2OC(C)C(OC3CC(C)(O)C(OC(=O)CC(C)C)C(C)O3)C(C2O)N(C)C PXUIVECFRJIQIG-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- UZQBOFAUUTZOQE-UHFFFAOYSA-N Pikromycin Natural products CC1CC(C)C(=O)C=CC(O)(C)C(CC)OC(=O)C(C)C(=O)C(C)C1OC1C(O)C(N(C)C)CC(C)O1 UZQBOFAUUTZOQE-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004189 Salinomycin Substances 0.000 description 1
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 description 1
- 241000593950 Streptomyces canus Species 0.000 description 1
- 241000187130 Streptomyces chartreusis Species 0.000 description 1
- 241001603876 Streptomyces conglobatus Species 0.000 description 1
- 241000970232 Streptomyces flavochromogenes Species 0.000 description 1
- 241000936695 Streptomyces gardneri Species 0.000 description 1
- 241000187179 Streptomyces tendae Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- WKDDRNSBRWANNC-ATRFCDNQSA-N Thienamycin Chemical compound C1C(SCCN)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 WKDDRNSBRWANNC-ATRFCDNQSA-N 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 229930195482 Validamycin Natural products 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- LSNBAGMWJRMBEO-VGBMZARNSA-N [(1r,3s,4e,6e,9s,10e,12e,14r,15s,18r)-9-hydroxy-6,12,15,18-tetramethyl-16,19-dioxo-14-(2-oxopropanoylamino)-17-oxabicyclo[13.2.2]nonadeca-4,6,10,12-tetraen-3-yl] acetate Chemical compound C1[C@H](OC(C)=O)\C=C\C(\C)=C\C[C@H](O)\C=C\C(\C)=C\[C@@H](NC(=O)C(C)=O)[C@@]2(C)C(=O)[C@H](C)[C@@H]1OC2=O LSNBAGMWJRMBEO-VGBMZARNSA-N 0.000 description 1
- RQLDKUSQKQMFCN-DOOXDOMHSA-N [(1s,2s,3s,4s,5r,6r)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl] carbamate Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@H]1[C@@H](N=C(N)N)[C@H](O)[C@H](OC(N)=O)[C@H](O)[C@H]1O RQLDKUSQKQMFCN-DOOXDOMHSA-N 0.000 description 1
- FFXJTOKFQATYBI-RUTGJBPVSA-N [(1s,3r,7r,8s,9s,10r,12r,13r,14e,16s)-9-[(2s,3r,4r,5s,6r)-4-(dimethylamino)-3-hydroxy-5-[(2s,4r,5s,6s)-4-hydroxy-4,6-dimethyl-5-propanoyloxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-13-hydroxy-8-methoxy-3,12-dimethyl-5-oxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1 Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C[C@@H]3O[C@H]3/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C FFXJTOKFQATYBI-RUTGJBPVSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- FHIABUHDBXFQIT-JSNQUVIDSA-N actinoidin Chemical compound O1[C@@H](C)[C@H](OC)[C@@H](N)C[C@@H]1OC(C1C(NC(C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)C(NC(=O)C2NC(=O)C(CC=3C=CC=CC=3)NC(=O)C(NC(=O)C(N)C=3C=CC(O)=CC=3)C(O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](N)C3)C4=CC2=C1 FHIABUHDBXFQIT-JSNQUVIDSA-N 0.000 description 1
- 108700031667 actinoidins Proteins 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940126574 aminoglycoside antibiotic Drugs 0.000 description 1
- 229950006334 apramycin Drugs 0.000 description 1
- XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 108010053278 avoparcin Proteins 0.000 description 1
- 235000019377 avoparcin Nutrition 0.000 description 1
- JWFVWARSGMYXRN-HTQQBIQNSA-N avoparcin Chemical compound O([C@H]1[C@H](C(N[C@H](C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(N[C@H](C4=CC(O)=CC(O)=C4C=4C(O)=CC=C3C=4)C(O)=O)=O)CC3=C(O[C@@H]4O[C@@H](C)[C@H](O)[C@H](N)C4)C=C(C(=C3)Cl)OC=3C=C2C=C(C=3O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)OC2=CC=C1C=C2)C=1C=CC(O)=CC=1)=O)NC(=O)[C@@H](NC)C=1C=CC(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)=CC=1)[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@H]1O JWFVWARSGMYXRN-HTQQBIQNSA-N 0.000 description 1
- 229950001335 avoparcin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229950004374 bluensomycin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- IJESDYFOSZHYNR-UHFFFAOYSA-N chalcomycin Natural products COC1CC(C)OC(OC2CCC(C)(O)C(=O)C=CC3OC3C(COC4OC(C)C(O)C(OC)C4OC)C(C)OC(=O)C=CC2)C1O IJESDYFOSZHYNR-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- NNQIJOYQWYKBOW-VMAXQDLPSA-N deacetoxycephalosporin-c Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@H](N)C(O)=O)[C@H]12 NNQIJOYQWYKBOW-VMAXQDLPSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- IUQPDUPFFGXZFJ-UHFFFAOYSA-N glebomycin Chemical compound NC(=N)NC1C(O)C(O)C(O)C(OC(N)=O)C1O.O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1O IUQPDUPFFGXZFJ-UHFFFAOYSA-N 0.000 description 1
- NEFPXJYTRGEZPG-TWGZDOMGSA-N hybrimycin Chemical class N[C@@H]1[C@@H](O)[C@H](O)[C@@H](C)O[C@@H]1OC1[C@H](O)[C@@H](O)[C@H](N)C(O)[C@@H]1N NEFPXJYTRGEZPG-TWGZDOMGSA-N 0.000 description 1
- YQYJSBFKSSDGFO-FWAVGLHBSA-N hygromycin A Chemical compound O[C@H]1[C@H](O)[C@H](C(=O)C)O[C@@H]1Oc1ccc(\C=C(/C)C(=O)N[C@@H]2[C@@H]([C@H]3OCO[C@H]3[C@@H](O)[C@@H]2O)O)cc1O YQYJSBFKSSDGFO-FWAVGLHBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- CFMSCYSETWZXRS-SNPFKJFCSA-N lactenocin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@@H]1[C@H]([C@@H](O)[C@@H](O)[C@@H](C)O1)OC)CC)C1O[C@@H](C)[C@@H](O)[C@@H](N(C)C)[C@@H]1O CFMSCYSETWZXRS-SNPFKJFCSA-N 0.000 description 1
- 229960004561 laidlomycin Drugs 0.000 description 1
- BBMULGJBVDDDNI-OWKLGTHSSA-N lasalocid Chemical compound C([C@@H]1[C@@]2(CC)O[C@@H]([C@H](C2)C)[C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC=2C(=C(O)C(C)=CC=2)C(O)=O)C[C@](O)(CC)[C@H](C)O1 BBMULGJBVDDDNI-OWKLGTHSSA-N 0.000 description 1
- 229960000320 lasalocid Drugs 0.000 description 1
- XJSFLOJWULLJQS-UHFFFAOYSA-N leucomycin A3 Natural products COC1C(OC(C)=O)CC(=O)OC(C)CC=CC=CC(O)C(C)CC(CC=O)C1OC1C(O)C(N(C)C)C(OC2OC(C)C(OC(=O)CC(C)C)C(C)(O)C2)C(C)O1 XJSFLOJWULLJQS-UHFFFAOYSA-N 0.000 description 1
- UFUYRGNJTFAODM-HQCAVAADSA-N macrocin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](O)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 UFUYRGNJTFAODM-HQCAVAADSA-N 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229950002784 maridomycin Drugs 0.000 description 1
- 101150086633 metAA gene Proteins 0.000 description 1
- 101150003180 metB gene Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- HUKYPYXOBINMND-UHFFFAOYSA-N methymycin Natural products CC1CC(C)C(=O)C=CC(O)(C)C(CC)OC(=O)C(C)C1OC1C(O)C(N(C)C)CC(C)O1 HUKYPYXOBINMND-UHFFFAOYSA-N 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960001851 narasin Drugs 0.000 description 1
- OXFYAOOMMKGGAI-JLTOUBQASA-N narbomycin Chemical compound C[C@H]1C[C@@H](C)C(=O)\C=C\[C@@H](C)[C@@H](CC)OC(=O)[C@H](C)C(=O)[C@H](C)[C@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1 OXFYAOOMMKGGAI-JLTOUBQASA-N 0.000 description 1
- OXFYAOOMMKGGAI-UHFFFAOYSA-N narbomycin Natural products CC1CC(C)C(=O)C=CC(C)C(CC)OC(=O)C(C)C(=O)C(C)C1OC1C(O)C(N(C)C)CC(C)O1 OXFYAOOMMKGGAI-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229950003438 neutramycin Drugs 0.000 description 1
- DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 description 1
- 229930189801 nocardicin Natural products 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- NSKGQURZWSPSBC-VVPCINPTSA-N ribostamycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](N)C[C@@H]1N NSKGQURZWSPSBC-VVPCINPTSA-N 0.000 description 1
- 229950004257 ristocetin Drugs 0.000 description 1
- 229960001548 salinomycin Drugs 0.000 description 1
- 235000019378 salinomycin Nutrition 0.000 description 1
- HJKXMQLJTKUBMG-INVUDJPSSA-N seldomycin Chemical compound N[C@H]1[C@@H](N)[C@H](OC)CO[C@@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)C[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N HJKXMQLJTKUBMG-INVUDJPSSA-N 0.000 description 1
- ACTOXUHEUCPTEW-KWBWCIJSSA-N spiramycin I Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@H]1CC[C@H](N(C)C)[C@H](C)O1 ACTOXUHEUCPTEW-KWBWCIJSSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
- C12N15/03—Bacteria
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Gene exchange in organisms of the genera Streptomyces and Nocardia is facilitated by using the technique of protoplast fusion. In this technique, physical and enzymatic barriers to gene exchange are overcome and the formation of hybrid cells is favoured. The process is particularly suitable for the development of hybrid strains having specific properties.
Description
This invention relates to a new process of facilitating genetic exchange witiiin the genus Streptanyces and Nocardia by protoplast fusion.
Genetic exchange, in conjunction with spontaneous mutation, is a natural method by which microorganisms maintain the variability needed to adapt to specific environments. Genetic exchange apparently occurs in nature, at least between members of the same species. Classical techniques used in the laboratory to effect genetic exchange between microorganisms include conjugation, DNA transformation and phage-mediated transduction. This exchange can involve either chromosomal or extrachromosomal genetic material. Genetic exchange can lead to hybrid strain formation by genetic recombination, plasmid transfer, heterokaryon formation and merodiploid formation. Finding laboratory conditions for efficient genetic exchange for microorganisms which do not possess efficient natural mating systems, however, can be very time consuming and in some cases fruitless. Difficulties encountered in DNA transformation include physical and enzymatic barriers to DNA uptake, such as cell walls and nucleases. In phagemediated transduction, a major difficulty encountered in developing a transducing system is isolation and identification of viruses with transducing properties for the specific microorganisms in question. The paucity of general principles and lack of a universal method to effect genetic exchange in - microorganisms has hindered the development of efficient techniques for genetic exchange in many microorganisms .
-2Nonetheless, genetic exchange remains a very important tool to increase variability within species which produce economically ar.d therapeutically important metabolites, such as antibiotics. Industrial applications of ό this tool include constructing strains which produce high levels of specific metabolites such as antibiotics, antitumor agents, enzymes and other microbial products having useful properties and constructing hybrid species which produce novel metabolites with useful properties.
A more recent method of effecting exchange of genetic material by forcing cell fusion has been used successfully in genetic studies with some eucaryotic organisms. Genetic exchange mediated by cell fusion had not been demonstrated with procaryotic microorganisms until lb Schaeffer et al. and Fodor and Alfodi devised a technique involving fusion of protoplasts and regeneration of cells of the genus Bacillus [P. Schaeffer et al., Proc. Nat. Acad. Sci. 73, 2151-2155 (1976) and K. Fodor and L. Alfoldi,
Proc. Nat. Acad. Sci. 73, 2147-2150 (1976)].
We have now discovered that it is possible to accomplish protoplast-fusion-induced genetic exchange in the procaryotic genus Streptomyces. This discovery permits the use of a general and thus extremely important technique for facilitating genetic exchange within the same or different species of the economically important genus Streptomyces.
We have also discovered that it is possible to accomplish protoplast-fusion-induced genetic exchange between the genus Streptomyces and the closely related genus Nocardia.
-347062
We have discovered that it is possible to facilitate genetic exchange within the genus Streptomyces by protoplast fusion. The process of this invention involves a multistep procedure consisting of 1) protoplast formation and stabilization, 2) genetic exchange by protoplast fusion, and 3) cell regeneration from fused protoplasts. The regenerated hybrid, including recombinant, strains produced are then screened for a specifically-desired property. Examples of desired properties include production of a known metabolite, such as an antibiotic or antitumor agent, in greater yield or in a strain from which it is more easily recovered. In the case of hybrid species, desired properties can include production of new, useful metabolites or improved production of known metabolites.
This invention provides a process of facilitating genetic exchange within the genera Streptomyces and Nocardia which comprises a) forming and stabilizing protoplasts by growing cells under conditions tnat sensitize them to lysozyme and treating the celis with lysozyme so as to remove the cell walls, b) mixing tne parental protoplasts to achieve fusion and c) regenerating cells from the fused protoplasts.
Protoplast formation and stabilization are accomplished by a) growing cells under conditions that sensitize them to lysozyme and b) treating these cells with lysozyme in a hypertonic buffer to remove cell walls and form protoplasts. Cell-wall removal may be accomplished by growing the cells for several generations in a medium containing
-447063 subinhibitory concentrations of glycine. Growth in the presence of glycine renders the streptomycete cell walls susceptible to the enzyme lysozyme [M. Okanishi, et al.,
J. Gen. Microbiol. 80, 389-400 (1974)]. Although in many cases cells grown in the absence of glycine will form protoplasts, the protoplasts are formed more slowly and less efficiently.
The medium can be any suitable liquid medium, such as nutrient broth or trypticase soy broth (TSB). After growth in the presence of glycine, the cells are treated to form protoplasts. This is typically done by washing the mycelia and resuspending in a hypertonic medium. A suitable hypertonic medium contains, for example, sucrose, magnesium ions, calcium ions, and phosphate. Medium P described by
Okanishi, et al., supra, is an example of a suitable hypertonic medium. Lysozyme (1 to 2 mg/ml) is added to the cell suspension, and the resulting suspension is incubated at about 30°-37°C until protoplast formation is complete (0.5 to 2.0 hours). Completion of protoplast formation can
be monitored by phase-contrast microscopy.
Protoplast fusion is achieved by mixing the protoplasts from the two parental organisms to induce the fusion of the parental protoplasts. The parental organisms may be strains of the same species (intraspecies) or dif25 ferent species (interspeoies). The protoplast mixture is centrifuged, and the protoplast pellet formed is resuspended in a small volume of hypertonic buffer. Fusion is enhanced by treating the parental protoplasts with polyethylene glycol (PEG). For example, a solution of PEG in hypertonic
-547 06S buffer (preferably a 40% solution) can be added to the resuspended protoplasts. The resulting fused protoplasts are plated on a hypertonic agar medium (e.g., medium R2 of Okanishi, et al., supra, or variations thereof).
Cell regeneration from the fused protoplasts is achieved by incubating the fused protoplasts on a hypertonic agar medium at a suitable temperature. A suitable temperature can be determined from the optimum temperatures at which the parental strains grow. To confirm genetic exchange it is preferable to use species containing suitable genetic markers such as auxotrophy or antibiotic resistance.
At this stage it is preferable, particularly in interspecies genetic crosses, to determine first the physiological growth state of the cells which is optimum for protoplast regeneration. The efficiency of protoplast regeneration can vary from <10^ to 5 χ ΙΟ-·*·, depending upon the physiological state of the cells prior to protoplast fusion. Patent Specification No. ΥΛν'1;’'6 of Baltz titled Improved Method of Obtaining Streptomyces Protoplasts Capable of Cell Regeneration, filed this even date, relates to a process of obtaining Streptomyces protoplasts which are capable of regenerating viable cells efficiently.
This process involves determining the optimum sta-te for protoplast reversion. Tne optimum state, the most competent state, is the transition phase Detween the exponential- and stationary-growth phases.
-54 7 0 6 2
The most competent state can be determined by monitoring the Streptomyces growth cycle. This is conveniently done using a turbidometric assay and measuring change in optical density (OD) at an absorbancy of 600 nm (A600). In general, Streptomyces species undergo fairly ii rapid exponential growth with cell-doubling times ranging from about 1.5 hours to several hours at low cell density (A600 less than 1.5) in soluble complex media. As cell growth reaches A600 readings of 1.5 to 4.0, cells enter a transition phase which precedes the stationary growth phase.
The transition phase may last from 2 to 24 hours, and cell mass may increase from 50% to 6-fold during this growth phase, depending on the species in question.
Putative hybrid, including recombinant, strains are then recloned and tested genetically by standard methods to confirm that they contain genes derived from both parents. True hybrid, including recombinant, strains are then tested for the desired beneficial property.
The process of this invention is useful for species within the genera Streptomyces and Nocardia which are normally inefficient or incapable of genetic exchange because of physical incompatibility. This method permits exchange and recombination of deoxyribonucleic acid (DNA) at very high frequencies. The method is especially useful for genetic exchange between mutant organisms of the same species, but also facilitates interspecies gene transfer.
The method is particularly valuable for strain development of the antibiotic-producing Streptomyces.
-747 0 63
For example, application of this method to Strepto4 myces fradiae strains readily gave recombinant yields of 10
-4 -3 to 10 per ml or frequencies of 10 to 10 per viable protoplast. In our laboratories previous attempts to obtain genetic recombinants of Streptomyces fradiae by standard methods [see D. A. Hopwood, Bact. Rev. 31, 373-403 (1967)] were unsuccessful: recombinant clones were not detected (i.e.,- less than 1 in 107). Thus, the technique of our invention increases the probability of detecting a specific 4
S. fradiae recombinational event by at least 10 -fold.
Our invention is also suitable for transmission of extrachromosomal DNA (plasmids), normally non-autotransmissible, from one Streptomyces species to another. Thus, under suitable conditions plasmid-encoded genes for antibiotic synthesis or regulation can be moved from a strain with poor metabolic potential for antibiotic synthesis into a more favorable strain.
In addition, the process of our invention extends to the closely related genus Nocardia. We have found that it is possible to accomplish, protoplast-fusion-induced gene transfer within the genus Nocardia and between the genus Streptomyces and the genus Nocardia.
Our invention will be especially useful for Streptomyces and Nocardia species of economic importance. Preferred Streptomyces and Nocardia species are those which produce antibiotics, such as aminoglycoside, macrolide, beta-lactam, polyether and glycopeptide antibiotics. Use of our method to effect genetic exchange when at least one parental organism is an antibiotic-producing species within
-84 7 0 6 2 the genera Streptomyces and Nocardia is, therefore, an example of an especially preferred application of our invention. For example, effecting genetic exchange when one parental organism is a macrolide-antibiotic-producing., an amino-glycoside-antibiotic-producing, a beta-lactamantibiotic-producing, a polyethyl-antibiotic-producing, or a glycopeptide-antibiotic-producing Streptomyces or Nocardia strain is a preferred application of our invention.
Streptomyces species which are known to produce aminoglycoside antibiotics include, for example: S. kanamyceticus (kanamycins), £. chrestomyceticus (aminosidine),
S. griseoflavus (antibiotic MA 1257), S. micrasporeus (antibiotic SF-767), S, ribosidificus (antibiotic SF733),
S.. flavopersicus (spectinomycin), S. spectabilis (actinospectacin), S. rimosus forma paromomycinus (paromomycins, catenulin), S. fradiae var. italicus (aminosidine), S. bluensis var. bluensis (bluensomycin), S. catenulae (catenulin), S. olivoreticuli var, cellulophilus (destomycin A), S. tenebrarius (tobramycin, apramycin), S, lavendulae (neomycin), S. albogriseolus (neomycins), S. albus var. metamycinus (metamycin), S. hygroscopicus var. sagamiensis (spectinomycin), S. bikiniensis (streptomycin), S. griseus (streptomycin), S. erythrochromogenes var. narutoensis (streptomycin), S. poolensis (streptomycin), S.. galbus (streptomycin), S. rameus (streptomycin), S. olivaceus (streptomycin), S. masheusls (streptomycin), S.. hygroscopicus var. iimoneus (validamycins), S. rimofaciens (destomycins), S. hygroscopicus forma glebosus (glebomycin), S. fradiae (hybrimycins neomycins), S. eurocidicus (anti-947063 biotic A16316-C)r- S. aguacanus (N-methyl hygromycin Β), S. crystallinus (hygromycin A), S_. noboritoensis (hygromycin),
S. hygroscopicus (hygromycins), S. atrofaciens.(hygromycin),
S_. kasugaspinus (kasugamycins) , S_. kasugaensis (kasugamycins) ,5 S. netropsis (antibiotic LL-AM31) , S_. lividus (lividomycins) ,
S_. hofuensis (seldomycin complex), and S_. canus (ribosyl paromamine).
Streptomyces and Nocardia species which are known to produce macrolide antibiotics include, for example: N. gardneri (proactinomycin), N. mesenterica (mesenterin), S. caelestis (antibiotic M188), S. platensis (platenomycin), S. rochei var. volubilis (antibiotic T2636), S. venezuelae (methymycins), S. griseofuscus (bundlin), S . narbonensis (josamycin, narbomycin), S. fungicidicus (antibiotic •^5 NA-181), S. griseofaciens (antibiotic PA133A, Β), S.
roseocitreus (albocycline), S. bruneogriseus (albocycline),
S. roseochromogenes (albocycline), S_ cinerochromogenes (cineromycin Β), S. albus (albomycetin), S. felleus (argomycin, picromycin), S. rochei (lankacidin, borrelidin),
2o S. violaceoniger (lankacidin), S. griseus (borrelidin), S.
maizeus (ingramycin), S. albus var. coilmyceticus (coleimycin), S. mycarofaciens (acetyl-leukomycin, espinomycin), S. hygroscopicus (turimycin, relomycin, maridomycin, tylosin, carbomycin), S. griseospiralis (relomycin), S_. lavendulae 25 (aldgamycin)-, S_. rimosus (neutramycin) , S. deltae (deltamycins), S. fungicidicus var. espinomyceticus (espinomycins),
S, furdicidicus (mydecamycin), S. ambofaciens (foromacidin D), S. eurocidicus (ftiethymycin), griseolus (griseomycin),
S_. flavochromogenes (amaromycin, shincomycins), £. fimbriatus
-104 7 0 6 2 (amaromycin), S. fasciculus (amaromycin), S. erythreus (erythromycins), S. antibioticus (oleandomycin), Ξ. olivochromogenes (oleandomycin), S. spinichromogenes var. suragaoensis (kujimycins), S_. kitasatoensis (leucomycin), 3. narbonensis var. josamyceticus (leucomycin A3, josamycin),
S. albogriseolus (mikonomycin), S. bikiniensis (chalcomycin), S. cirratus (cirramycin), S. djakartensis (niddamycin), S_. eurythermus (angolamycin), S. fradiae (tylosin, lactenocin, macrocin), !3. goshikiensis (bandamycin), S. griseoflavus (acumycin), S_. halstedii (carbomycin), S. tendae (carbomycin), S. macrosporeus (carbomycin), ;S. thermotolerans (carbomycin), and S. albireticuli (carbomycin).
Streptomyces and Nocardia species which are known to produce beta-lactam antibiotics include, for example: S. lipmanii (A16884, MM 4550, MM 13902), N. uniformis (nocardicin) , S. ciavuligerus (A16886B, clavulanic acid), S. lactamdurans (cephamycin C), S. griseus (cephamycin A, Β),
S. hygroscopicus (deacetoxycephalosporin C), S. wadayamensis (WS-3442-D), S. chartreusis (SF 1623), S. heteromorphus and S. panayensis (C2081X); S. cinnamonensis, S. fimbriatus, S. halstedii, S. rochei and S. viridochromogenes (cephamycins A, B); S. cattleya (thienamycin); and S. olivaceus, S. flavovirens, S. flavus, S. fulvoviridis, S. argenteolus, and S. sioyaensis (MM 4550 and MM 13902).
Streptomyces species which are known to produce polyether antibiotics include, for example; S. albus (A204, A28695A and B, salinomycin), S. hygroscopicus (A218, emericid, DE3936), A120A, A28695A and B, etheromycin, dianemvcin), S. griseus (grisorixin), S. conglobatus (ionomycin), S.
-1147 0 6 2 eurocidicus var. asterocidicus (laidlomycin), S. lasaliensis (lasalocid)/ S. ribosidificus (lonomycin), S. cacoai var. asoensis (lysocellin), S. cinnamonensis (monensin), S. aureofaciens (narasin), S. gallinarius (RP 30504), S. longwoodensis (lysocellin), S. flaveolus (CP38936), S. mutabilis (S-11743a), and S. violaceoniger (nigericin).
Streptomyces and Nocardia species which are known to produce glycopeptide antibiotics include, for example: N. fluctiferi (ristomycin), N. lurida (ristocetin), H. actinoides (actinoidin), S. orientalis and S. haranomachiensis (vancomycin); S. candidus (A-35512, avoparcin), and S. eburosporeus (LL-AM 374).
Other useful antibiotic-producing steptomyces species of interest include strains of £5. coelicolor,
S. capreolus and S. lincolnensis.
Processes wherein genetic exchange is intraspecies suitably include those wherein the exchange is between strains of £3. fradiae, S. griseofuscus S. cinnamonensis :3. lipmanii S. aureofaciens S. candidus S.tenebrarius £L· erythraeus S. griseus S hygroscopicus S_. clavuligerus £5. bikiniensis S.coelicolor S. ambofaciens £3. albogriseolus, S. albus S. aquacanus S. capreolus S. cattleya S. crystallinus S. kanamyceticus S. kasugaensis S. kasugaspinus £. kitasatonsis S lactamdurans S. lasaliensis S. lavendulae S. lincolnensis S. narbonensis S. noboritoensis EL orientalis or S. rimosus.
In order to illustrate more fully the operation of this invention, the following specific examples are provided;
EXAMPLE 1
Streptomyces fradiae auxotrophic mutants Al (leu)and D6 (met)were used. Liquid nitrogen suspensions of vegetative cells (0.5 ml) were inoculated separately into 50 ml of trypticase soy broth (TSB) containing 0.4% glycine and 0.4% maltose. The cultures were incubated at 37°C for 18 hours with aeration (250 RPM; 2.5-cm stroke). The mycelia were washed by centrifugation and then resuspended in 20 ml of medium Ρ (M. Okanishi, et al., supra) containing lysozyme (1 mg/ml). The suspended mycelial cells were incubated for 2 hours at 30°C. The resulting protoplasts were mixed, centrifuged, and then resuspended in 1 ml of medium P. Solutions of PEG 6000 in
-124 7 0 6 2 medium Ρ (0.9 ml) at various concentrations were each added to 0.1 ml of the protoplast suspension to induce cell-membrane fusion. The fused protoplasts were immediately diluted in medium P and plated on a modified R2 medium (Okanishi, et al., supra, supplemented with 20% sucrose and containing no casamino acids). The results are summarized in Table 1.
-1347 0 63
I—I
Table
fi 0 efi •rl 44 Φ > C ϋ •rl fi φ ε 3 0 σ o φ φ k ft UH 03 >! 44 0 ζ· c Φ Φ fi 3 •rl CP Φ rH ε k δ ft Ό k φ Φ c ft α 0 •H -P Φ C •ri
ίΜ Ο νο ιη ιΛ «—1 CM cn m CM rH Ο
η cn η· cn cn CM Ο Ο ο © o O r-i rH rH rH rH rH X X X X X X cn σι rH σι σι c\ <3· m rH n· CM rH
I
Φ ft β
c •H
Φ k
c
Φ fi u
ft ft
UH ϋ
Φ
U-I
UH ft c
•rf
4J rH
T3 Φ xj ft Ό ft <
ω <5 rH ft
Ο Ό 44 Φ ο τι k 'ϋ ft <
β ο
•Η •Η τί β· ο
V
0 0 Ο ft ft dP 0 ft ft <#» Ο ft ft 0 ft ft ft ft © © © ft ft CM © a¥> © <& © * tn tn tn cn © n* ft ft ft ft rH rH rH rH rH s ε s ε S e σ\ σι σι σι σν cn © © © © o o
+ + + + + + tn 03 tn 03 01 02 rH rH rH rH rH rH r-4 rH rH Φ Φ Φ Φ Φ Φ ϋ 0 ϋ 0 0 0 rH rH rH ε ε ε ε ε ε rH rH rH rH rH rH © © © © © ©
cm cn η* ιη νο ε
ιη
XJ ft ο
k ο
Ο k
α
ΜΗ ο
γΗ ε
\ ω
k ο
>
•Η >
k filter sterlized (Millipore .45 microns) (Millipore is a Registered
I φ Ό ω φ ft k * EH
14'
7 0 6 2
The above mating was repeated using a 40¾ solution of filter-sterilized PEG. A recombination frequency of 3.5 x 10^ recombinants per ml was obtained. The recombinant colonies were recloned on nonhypertonic selective medium and tested for stability. Of the ten recombinants tested, all were prototrophic and stable (did not lose selected marker on extensive subculture under nonselective conditions).
EXAMPLE 2
Streptomyces fradiae auxotrophic mutants were
Ιθ used. At least one parent strain contained two auxotrophic markers and a spectinomycin resistance (spc) marker. Each of the genetically-marked S_. fradiae strains was grown in TSB containing 0.4% glycine. When growth reached an optical density of 1.5 to 5, as measured at 600 nm in a colorimeter (Baush and Lomb), the mycelia were washed twice by centrifugation and then were resuspended in medium Ρ (M. Okanishi, et al., supra). Lysozyme (1 to 2 mg/ml) was added to the suspension. The suspended mycelial cells were incubated for 0.5 to 2 hours at 30° or 34°C. The resulting protoplasts 2Q were mixed (0.5 ml of each parent suspension). The mixture was washed several times by centrifugation, resuspending in medium P and finally resuspending in 0.1 ml of medium P. A solution of 40% PEG 6000 in medium P (0.9 ml) was added to the final suspension to induce cell-membrane fusion.
Protoplast fusion was confirmed by phase-contrast microscopy. The fused protoplasts were immediately diluted into one of the following media: medium P containing 40% PEG, medium P, or distilled water. The dilutions were plated on medium R2 (Okanishi, et al., supra) to allow detection of
-154 7 0 6 3 recombination and regeneration of prototrophic recombinants. The R2 medium used contained asparagine instead of proline as nitrogen source. Recombinants were counted after 10 to 24 days incubation at 34°C. In many of the crosses the prototrophic recombinants were further tested for the presence of an unselected marker (spectinomycin resistance) to eliminate single mutant reversion artifacts. Additional controls were carried out to confirm recombination. Total recombinants are based on original volumes of mixed proto8 9 £0 plasts which generally contained from 10 to 10 protoplasts/ml, as determined by direct counting in a hemocyto.meter.
A summary of several genetic crosses by protoplast fusion is given in Table 2.
-164 7 0 6 2
IS
CN
Table
2ο
-Η 4J □ β ω > Φ X C -Ρ 0. 3 ϋ) 0 β •Η Ρ •Η Ul 4J •Ρ 'j Φ 0 X -Ρ φ 0 X Ρ 75 X < t, 3 * γ—1 α w ε Ή •Ρ \ Ω β υι X Φ -Ρ 0 β β Ρ •Η φ •Ρ Ω Ρ 0 ε ρ 4J 0 Φ 0 ο > Ρ φ φ X X X
β
Ο •Η
4J ρ©
Ο
X μ*
CN «
X χ
ο
X
Ο
X X ι—I © © Ο © Γ*. V •Η
Ό
Ο
S >
W ρ
Φ ,Χ
Ρ
Φ
X rp
Φ
Ω α
φ ρ
φ
X
Ο
Ω
X Οι
Ο Ω CN X X +
X ο
CN
X β
ο
Β ρ
Φ
Φ
Ρ
4->
β
Φ μι
Φ
X β
•Η
4J •Η
Ό
C
Ο
ΩΙ ΩΙ Ω
-Μ -Ρ +J I
Φ Φ Φ I εΙ ει ει
<1 <} <1
4-11 -Ρ| 4J φ φ φ εί ει εΙ
Η CM
si si si
ΦΙ ΦΙ ΦΙ <1 <1 <1 4J -Ρ Ρ| Φ Φ Φ εΙ εΙ εΙ rf ΙΖ) ©
7 0 6 2
Table 2 (continued)
-rt -P O fi 0 >, m x: s -p fe Ο 0 O C *rt k •rt 0 P XJ 0 O O fe -P 0 0 k cn fe <3 k 0 irt 0 0 6
•rt 4J \ X C 0 a d -P o c c k -rt (fl 4J J3 4J 0 S k Ρ O 0 0 O > k 0 0 fe fe Ci c
o e •rt 3 +j -rt 3 T3 frt 0 •rt s a
4J β
£ Μ -P fe (fl k
Eh in o
rrt irt ©
(rt
V fe fe
P 03 CQ CQ Q β P •H -P 0 0 0 0 0 > k £l £1 £ O 0 fe
•p £
• ι <-> rt m 0 r- 0 σι k (rt
-* 0) 0 in +J © 0 c l O' frt -rt r* 0 m 0 XJ rrtl · (CIO •rt •pLc
0la o - k Ό «Ρ o o o « > £
CU 0
X 0 k
M-l (fl 0
0 k 0 0 O X JZ k 4J 0 £
. k η υ (fl 4-)(0
Q* 0 £|0 β
Ο Ό rrt •rt C ε
-P (fl \ • Sj , ι ffl I t
T3 fl ,01 SJ 0 β c σ 3. 01 β 0 •rt •rt (fl |© °1 £ τ5 0 in ki k 0 0 * (til 0 fi Ό < |o 4J •rt P 4-> 0 £ k ol •P Ό k 0 £ |0 0 0 o £ •P P k Φ c 0 0 (fl x 0 ffl Q S Sh 4J K <1 >
-1847062
As was the case in Example 1, a lower, but significant, level of recombination was obtained by centrifuging the protoplasts and resuspending in medium P without
PEG. This level of protoplast fusion is presumably due to ++ the presence of Ca in the buffer. Dilution of the protoplasts in distilled water reduced the number of recombinants by LOO-fold. Virtually all of the genetic recombinants tested contained the spc marker from the strain carrying the metA arg markers, ruling out the possiblity that reversion
IO of the metB strain might account for the data. The doubly marked auxotrophic strain has never been shown to revert to prototropy, thus eliminating reversion of this strain as an explanation of the results. The other controls in Table 2 give additional evidence that recombination does indeed take place after protoplast fusion. Upon recloning, all putative recombinants were shown to be stable. The S. fradiae strain used is one which produces the antibiotic tylosin. Many genetic recombinants of this S. fradiae were shown to be tylosin producers.
EXAMPLE 3
Streptomyces griseofuscus was used in these genetic crosses. The procedures were the same as those used in Example 2 except that: 1) the TSB was supplemented with 0.8% glycine and 2) recombinant colonies were counted after
7 days incubation at 34eC. Results are summarized in Table
3. In all six conditions protoplasts were treated with PEG, diluted in medium P and plated on medium R2. In all cases, the frequency of genetic recombinants was from 103 to 4
-fold higher than background prototrophic revertants.
-1910
u Ul rd g •rt μ \ C Ul a « μ 0 c fi u •id <ΰ μ μ μ 0 s μ μ 0 Φ 0 0 > μ ω Φ & Oi oi
*9·
Ο η
ΓΩ «9* rd
Ο © Ο rd ι—t r-t tt tt tt r-t rd
CM © O • · rd · •9* ’Μ* V H <10
Table
4706S
EXAMPLE 4
Streptomycss fradiae (met) and Streptomyces bikiniensis (nic ade; were used. Each culture was incubated according to the procedure described in Example 1. Crosses made between the strains are listed in Table 4 where conventional mating techniques are compared to the protoplast fusion technique. Table 4 demonstrates that protoplast fusion gives at least a 200-fold increase in recombination frequency compared to conventional mating procedures.
-2110
A7062
01 μ 01 c • <ο 0 β μ U 0 - to ε . ·μ s 0 01 01 μ μ 3 *0 μ μ fa 01 οι jj 01 ο μ υ 01 01 0) ♦μ 01 <ΰ μ 0 >μ 01 β •μ Cu 01 .01 JJ 0 □ nJ JJ ζρμ 0
tu ω s-ι Μ ΒΌ. fa 41 > >, C -Q
«Φ 0 tP •μ CO 01 JJ •μ 01 μ (β >·μ J3 S ο <ΰ Φ H ι-ι ·μ B •3 CUO 6 S 01 0 Μ S υ 01 01 01 fa 0) 01 0 0 «4 μ μ 0 Ο ο β 01 01 0 0) 01 01 •μ ·μ •rl ο ο μ 0) 01 φ cucu cu 01 01 ε μ μ Ο- .0) 0) Ο μ μ α c
CO 1 © μ X Γ j > 1 1 ·Φ CP 1 1 · 0 CN μ V 0 01 μ α 01 μ 0 μ £ ιΰ © £ > ι C © © τι 0 ι «μ 01 (—4 ο μ 0 «μ χ ο □ 1 0) χ © I μ «- 01 μ m 01 01 ν ν β Τ3 Ω Φ u-i 0 0 co © •μ j 1 μ τι β o © •μ οι μ μ μ μ μ I •μ 0 01 XX 1 η ο α β μ μ μ © μ 0) ιΰ .· · to to a
Λ Λ J2 ω co αι + + +
Ul μ
t—{
Ό .
>
•rl +J tO
JJ
0) tP >
β
CP μ
.fa c
o
-rl
JJ
•μ β
•rl cn β
a oi ΰ
to oil w
•rl , 01 >i μ
(ϋ β
<
jJ β
β β
♦rl i
ο □
fa cafwlwf
224 7 0 6 3
Table 4 (cont'd) r·*» ι
o i—l
XXX Γ- T <*>
H rf*)
V V
ΙΟ Γ*» CO I 1 I o o ©
XXXI cm *j· cn
V V
Φ Φ fi fi •Η •Η >1 Ό Ό ϋ fi fi c Ρ Ρ Φ Ψ4 iw 3 σ1 « • Φ cqIcqi P C t. ϋ •Η χ X fi fi 0 0 fi •rl •rt Φ cn ιη cn W «Ρ α •Η •Η rl 3 fi ω η cn cn fed fi 3 C fi fi •r| CQ φ Φ Φ Φ 4J Λ •Η •rl •H fi ω ε fi fi c •r| fi ο •rl •rl •H Ό r—1 ο X X X fi CL φ •rl •rl rl P 0 ε Δ X] 42 44
4»
P &
in >1 rd fi c
<
fi fi fi «rl ί
Φ
X tnlwlcnltn I >
Cn >irH fi 0 0 43 ι—I 0. 0 P
4J Ό •Η φ
r—1 4J P •rl ϋ Φ 42 Φ X fi r—1 P +J Φ fi CQ CQ a
Ό
Φ P 4J Φ ϋ X Φ P ι—I fi φ a co
4J c
fi c
•rl · a o ε z o
o φ
(ύ
424242 42414242^4242 W CQ CQ CQ CQ CO tfl ω CQ VI
IIIIII
-2310 rH r·I •μ
A β
gμ
Φ cn
TJ β
ra cn Φ A μ aw
A o rH · W μ Φ μ * ο ·μ ο c a c ιμ ο μ ο •μ φ (—ι G A S Ο 3 3 Ο
Ο Α TJ μ 3 φ φ σ» ϋ a α β ϋ Α Φ ·μ φ μ η α φ ω φ ο $ Μ d Φ w Ό Φ g Α Α Ο G A W
Ό 3 0 G μ μ W O •rl ο Ο CJ 5 A A U-i 3 fa g ΜΗ Φ 0 O TJ g ϋ Φ Φ A I 0 μ • W A . μ Φ β - 3 4J cn
Table 4 (cont'd)
cn 3 O' Φ ·μ q •μ 3 μ ω •μ *3 TJ φ ffl Φ Φ μ g w μ α 0 Η Φ Α o Φ 3 ο > G ·* 3 •μ ο α φ >1 A G > θ' W ϋ τ? 3-μ Ο G Φ Φ G Α •μ 0 rH Α ·μ ·μ Ο -μ Φ 3 A W Α A (Π rH g Ο fa •μ fa Ο fa μ TJ φ ϋ ο c Α Ό Φ φ g 0 a c μ μ • o 3 Φ μ W G A3 φ ♦μ tn OTJ ϋ ω c φ 3Η μ β H • ΟΆ Φ Η 3 φ A G 3 3 g •μ 3 CM •μ ϋ β β g 10 g ·μ ο ω TJ «μ cn ο β μ β φ id TJ rH «μ Ο ΜΗ 3 Α •μ C s_^ aw φ α Α 3 Φ ΜΕ φ CM μ - φ Η • g *3* ο3 ·μ + Φ cn 3 m μ ω β W •μ 1 Φ 0 β II TJ cn A rH θ' Φ Φ Γ* μη β ο ·μ Α Α S CM di ·μ ο ω Α ω
«μ cm co
40% PEG in medium P (filter-sterilized) ><
Α
Ό
Φ
Ο tj β
•μ β
Ο μ
w
ΜΗ
Α
Μ rH fa
Ο
Α
Ο μ
fa
Α μ
ο
Ν *Ο φ
ο
Ό
Ο μ
fa ω
φ •μ rH
Ο ϋ
Α ω
rH rH «<
in
24·
7 0 6 2
EXAMPLE 5
Several interspecies crosses were studied using the protoplast-fusion technique. Strains were incubated overnight under optimal cultural conditions with growth5 limiting concentrations of glycine. Protoplasts were isolated from each strain by treatment with lysozyme (1 mg/ml) at 30°C for 1 to 4 hours. The resulting protoplasts were mixed and resuspended in medium P (see Example 1). A solution of 40% PEG 6000 in medium P (0.9 ml) was added to the final suspension to induce cell-membrane fusion. As a control, 0.1 ml of the protoplast suspension was resuspended in 0.9 ml of medium P. The treated and nontreated protoplasts were immediately diluted in medium P and plated on selective medium (R2 without casamino acid supplementation). The following strains were used:
-2510
471)62
CO
Phenotype
Ch
Φ
ΟΙ φ| ρ
wl •Ρ 1 43 I
Ρ 3 Φ Φ ί eWt ω I ω 1 •ρ NQ Ω 4i Hb £5
Ό «Η ϋ
φ ο
•Ρ •Ρ ΰ
φ
Ρ
Χί «Ρ β
φ
Φ|
Ό
ΦΙ sl&l
CM
X β
Ο φ
4J
Φ
Ρ φ
β
cm m cap represents resistance to chloramphenicol at 20 pg/ml; the remaining markers are axjxotrophic
-264 7 0 6 2 m
Φ ι—4
Λ ιΰ gM
0) £
cu ο
ri μ
Ο μ
Ο μ
Ο.
Ο
U
1) ϋ
£ ζ
es ri φ
α
Ν* ατ>
> •riN μ
ϋ rt φ ·Η «μ Ό Φ Φ ϋ) Σ «
(fl μ
U
XX XX ο ο ιη ο
ΓΩ ΓΩ
V
ΓΩ Ω4 03 ν
XX XX XX © ο σ\ cn ο ο e-i 0 © ο
Ώ ΓΩ ιη ΓΩ V γ-4 Ο © © <*Ω
Φ Φ C C •ri *ri
rf rf C fi u □ φ φ + + Z TJ a ct rt rt rt rt ϋ 0 + +
+ +
CN CN CN CN CN CN CN CN CN CN CN CN CN tX os OS OS OS OS OS OS os 05 oS OS os QS
+ I +1 + ι
Μ* rf rf I I
Γ- Γ> ΙΟ ιθ f-4 r-4 in in CN CN ι-H ι—I rf rf
I I
CN CN in in i-η h
ω w rf & μ μ w w in in z 2 CO CD W W i—4 i—1 in in CN ΓΩ ΓΩ 3 >3 (fl (fl ΓΩ ΓΩ rf rf Vi Vi CN CN Vi Vi c c 1 Em Em •ri •ri 00 CO 3 £ (fl (fl Φ Φ < < W W rri r-1 ΓΩ ΓΩ •ri ri 3 3 •ri •ri 0 0 ri ri ri ri ϋ o (fl (fl Φ Φ a SJ cn Cfl rt rt Φ Φ rt rt 3 3 rt rt 0 0 •ri •ri ri ri σ Cn +4 μ •α ό •ri •ri ri ri W (fl Λ Λ •ri •ri 0 0 •ri •ri TJ Ό XJ 42 fi c Φ Φ r-4 i—4 Φ Φ Ό Ό rt rt μ μ Φ Φ fi C 3 3 ri ri fi C ri ri fi fl Φ Φ > > 3 3 rt rt μ μ ri ri 0 0 μ μ rt rt rt rt o o Φ Φ ε g »—1 «—4 • « rt rt • • ϋ □ » « • • cn w • • fi fi cnlwl wlw wlwt 2 2 fi c • « •ri •ri cnlwl X X ϋ ϋ X X X X X X
Ό
Φ
N •ri at 20 mcg/ml—added after 24 hrs incubation
Claims (61)
1. A process for facilitating genetic exchange within the genera Streptomyces and Nocardia which comprises A) forming ani stabilizing protoplasts by growing cells under conditions that sensitize them to lysozyme and treating the cells with lysozyme so as to remove the cell walls. B) mixing the parental protoplasts to achieve fusion and C) regenerating cells from the fused protoplasts.
2. The process of claim 1 wherein protoplasts are formed during the transitional growth phase.
3. The process of claims 1 or 2 wherein protoplasts are formed by growing cells on a hypertonic nutrient medium in the presence of a non-inhibiting concentration of glycine, adding lysozyme and incubating the resulting suspension at 30 to 37°C.
4. The process of any of claims 1 to 3 which coiparises enhancing protoplast fusion by treating the protoplasts with polyethylene glycol.
5. The process of any of claims 1 to 4 wherein the genetic exchange facilitated is intraspecies.
6. - The process of any of claims 1 to 4 wherein the genetic ecchange facilitated is interspecies.
7. The process of any of claims 1 to 6 wherein the genetic exchange is wwithin the genus Streptomyces.
8. The process of any of claims 1 to 6 wherein the genetic exchange is wri.thin the genus Nocardia.
9. The process of any of claims 1 to 6 wherein one parental organism is an antibiotic-prcducing species wri-thin the genera Streptomyces and Nocardia·
10. The process of claim 9 wherein the genetic exchange is wri-thin the genus Streptanyces.
11. The process of claim 9 wherein the genetic exchange is within the genus Nocardia. -284 7 0 6 2
12. The process of any of claims 1 to 6 wherein one parental organism is an aminoglycoside-antibioticproducing species.
13. The process of claim 12 wherein one parental organism is selected from S kanamyceticus, S. chrestomyceticus, S. griseoflavus, S. microsporeus, S. ribosidificus, S.flavoperisicus, ,S. spectabilis, S. rimosus forma paromomycinus, S. fradiae var. italicus, S. bluensis var. bluensis, S. catenulae, S. olivoreticuli var. cellulophilus, S. tenebrarius, S. lavendulae, S. albogriseolus, S. albus var. metamycinus, S. hygroscopious var. sagamiensis, S. bikiniensis, S, griseus, S. erythrochromogenes var. narutoensis, S. poolensis, S. galbus, S. rameus, S. olivaceus, S. mashuensis, S. hygroscopicus var. limoneus, S. rimofaciens, S. hygroscopicus forma glebosus, S. fradiae, S. eurocidicus, S. aquacanus, S. crystallinus, S. noboritoensis, S. hygroscopicus, S. atrofaciens, S. kasugaspinus, S. kasugaensis, S. netropsis, S. lividus, S. hofuensis, and S, canus.
14. The process of any of claims 1 to 6 wherein one parental organism is a macrolide-antibiotic-producing species.
15. The process of claim 14 wherein one parental organism is selected from S. caelestis, S. platensis, S. rochei var. volubilis, S. venezuelae, S. griseofuscus, S, narbonensis, S. fungicidicus, S. griseofaciens, S. roseocitreus, S. bruneogriseus, S. roseochromogenes, S. cinerochromogenes, S albus, S. felleus, S. rochei, S. violaceoniger, S. griseus,,S. maizeus, -294 7 0 6 2 S. albus var. coilmyceticus, S. mycarofaciens, S hygroscopicus, S. griseospiralis, S. lavendulae, S. rimosus, S. deltae, S. fungicidicus var. espinomyceticus, S. furdicidicus, S. ambofaciens, S. eurocidicus, S. griseolus, S flavochromogenes, S. fimbriatus, S. fasciculus, S. erythreus, S. antibioticus, S. olivochromogenes, S. spinichromogenes var. suragaoensis, S. kitasatoensis, S. narbonensis var. josamyceticus, S. albogriseolus, S. bikiniensis, S. cirratus, S. djakartensis, S. eurythermus, S. fradiae, S, goshikiensis, S. griseoflavus, S, halstedii, S, tendae, S. macrosporeus, S. thermotolerans, N, gardneri, N. mesenterica and S. albireticuli.
16. The process of any of claims 1 to 6 wherein one parental organism is beta-lactam-antibiotic-producing species.
17. The process of claim 16 wherein one parental organism is selected from S, lipmanii, S. clavuligerus, S. lactamdurans, S. griseus, S. hygroscopicus, S. wadayamensis, S, chartreusis, S. heteromorphus, S. panayensis, S. cinnamonensis, S. fimbriatus, S. halstedii, S. rochei, S. viridochromogenes, S. cattleya, S. olivaceus, S. flavovirens, S. flavus, S. fulvoviridis, S. argenteolus, N. uniformis and S. sioyaensis.
18. The process of any of claims 1 to 6 wherein one parental organism is a polyether-antibiotic-producing species.
19. The process of claim 18 wherein one parental organism is selected from S. albus, S. hygroscopicus, S. griseus, S, conglobatus, -304 7 0 6 2 S. eurocidicus var. asterocidicus, S. lasaliensis, S. ribosidificus, S. cacaoi var. asoensis, S. cinnamonensis, S. aureofaciens, S. gallinarius, S. longwoodensis, S. flaveolus, S. mutabilis, and S. violaceoniger.
20. The process of any of claims 1 to 6 wherein one parental organism is a glycopeptide-antibiotic-producing species.
21. The process of claim 20 wherein one parental organism is selected from S. orientalis, S. haranomachiensis, S. candidus, N. fructiferi, N. lurida, N. actinoides, and S. eburosporeus.
22. The process of claim 5 wherein the genetic exchange is between S. fradiae strains.
23. The process of claim 5 wherein the genetic exchange is between S. griseofuscus strains.
24. The process of claim 5 wherein the genetic exchange is between S. cinnamonensis strains.
25. The process of claim 5 wherein the genetic exchange is between S. lipmanii strains.
26. The process of claim 5 wherein the genetic exchange is between S. aureofaciens strains.
27. The process of claim 5 wherein the genetic exchange is between S. candidus strains.
28. The process of claim 5 wherein the genetic exchange is between S. tenebrarius strains.
29. The process of claim 5 wherein the genetic exchange is between S. erythreus strains.
30. The process of claim 5 wherein the genetic exchange is between S. griseus strains. -314 7 0 6 2
31. The process of claim 5 wherein the genetic exchange is between S. hygroscopicus strains.
32. The process of claim 5 wherein the genetic exchange is between S. clavuligerus strains.
33. The process of claim 5 wherein the genetic exchange is between £L bikiniensis strains.
34. The process of claim 5 wherein the genetic exchange is between S. coelicolor strains.
35. The process of claim 5 wherein the genetic exchange is between S_. albofaciens strains.
36. The process of claim 5 wherein the genetic exchange is between S. albogriseolus strains.
37. The process of .claim 5 wherein the genetic exchange is between S_. albus strains.
38. The process of claim 5 wherein the genetic exchange is between S. aquacanus strains.
39. The process of claim 5 wherein the genetic exchange is between S. capreolus strains.
40. The prooess of claim 5 wherein the genetic exchange is between S. cattleya strains.
41. The process of claim 5 wherein the genetic exchange is between S. crystallinus strains.
42. The process of claim 5 wherein the genetic exchange is between S. kanamyceticus strains.
43. The process of claim 5 wherein the genetic exchange is between £5. kasugaensis strains.
44. The process of claim 5 wherein the genetic exchange is between S. kasugaspinus strains.
45. The process of claim 5 wherein the genetic exchange is between S. kitasatoensis strains. -324 7 0 6 2
46. The process of claim 5 wherein the genetic exchange is between S. lactamdurans strains.
47. The process of claim 5 wherein the genetic exchange is between S. lasaliensis strains.
48. The process of claim 5 wherein the genetic exchange is between £. lavendulae strains.
49. The process of claim 5 wherein the genetic exchange is between S. lincolnensis strains.
50. The process of claim 5 wherein the genetic exchange is between S. narbonensis strains.
51. The process of claim 5 wherein the genetic exchange is between S. noboritoensis strains.
52. The process of claim 5 wherein the genetic exchange is between S. orientalis strains.
53. The process of claim 5 wherein the genetic exchange is between S. rimosus strains.
54. The process of claim 6 wherein the genetic exchange is between S. fradiae and S. bikiniensis.
55. The process of claim 6 wherein the genetic exchange is between S. fradiae and S. cinnamonensis.
56. The process of claim 6 wherein the genetic exchange is between S. lipmanii and S. tenebrarius.
57. The process of claim 6 wherein the genetic exchange is between S. cinnamonensis and S. aureofaciens.
58. The process of claim 6 wherein the genetic exchange is between S. aureofaciens and S. candidus.
59. The process of claim 6 wherein the genetic exchange is between S. lipmanii and S. clavuligerus.
60. The process of claim 6 wherein the genetic exchange is between N. erythropolis and £3. coelicolor. -334 7 0 6 2
61. A process for facilitating genetic exchange within the genera Streptomyces and Nocardia according to claim 1 substantially as hereinbefore described with particular reference to any of Examples 1 to 5.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81209777A | 1977-07-01 | 1977-07-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
IE781318L IE781318L (en) | 1979-01-01 |
IE47062B1 true IE47062B1 (en) | 1983-12-14 |
Family
ID=25208489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE1318/78A IE47062B1 (en) | 1977-07-01 | 1978-06-30 | Method of facilitating genetic exchange in streptomyces and nocardia by protoplast fusion |
Country Status (13)
Country | Link |
---|---|
JP (1) | JPS5414580A (en) |
AR (1) | AR220714A1 (en) |
BE (1) | BE868473A (en) |
CA (1) | CA1105859A (en) |
CH (1) | CH639694A5 (en) |
DE (1) | DE2827963A1 (en) |
FR (1) | FR2396082A1 (en) |
GB (1) | GB1602074A (en) |
HU (1) | HU189441B (en) |
IE (1) | IE47062B1 (en) |
IL (1) | IL55004A0 (en) |
IT (1) | IT1098354B (en) |
NL (1) | NL7807003A (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07112437B2 (en) * | 1982-03-05 | 1995-12-06 | 味の素株式会社 | Method for producing fermentation product from starch |
EP0125468B1 (en) * | 1983-04-13 | 1992-10-28 | Crop Genetics International Corporation | Agricultural-chemical-producing endosymbiotic bacteria and method of preparing and using same |
HU194306B (en) * | 1983-05-16 | 1988-01-28 | Gyogyszerkutato Intezet | Process for influencing biosynthesis of antibiotics with in vivo genetical recombination |
JPS63217165A (en) * | 1987-03-03 | 1988-09-09 | Sanyo Electric Co Ltd | Hot air controller of hot air type heater |
US5773221A (en) * | 1995-12-15 | 1998-06-30 | Oceanix Biosciences Corporation | Method of recovering a biological molecule from a recombinant microorganism |
DE19629271A1 (en) * | 1996-07-19 | 1998-01-22 | Wolfgang Prof Dr Piepersberg | Isolating DNA from microorganisms that can not be cultured |
US6326204B1 (en) * | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
CN107151264B (en) * | 2011-03-23 | 2021-11-23 | 浙江医药股份有限公司新昌制药厂 | Novel glycopeptide antibiotic derivative, pharmaceutical composition, preparation method and application thereof |
-
1978
- 1978-05-23 GB GB21350/78A patent/GB1602074A/en not_active Expired
- 1978-06-26 DE DE19782827963 patent/DE2827963A1/en active Granted
- 1978-06-26 AR AR272717A patent/AR220714A1/en active
- 1978-06-26 IL IL7855004A patent/IL55004A0/en not_active IP Right Cessation
- 1978-06-26 CA CA306,181A patent/CA1105859A/en not_active Expired
- 1978-06-27 BE BE1008953A patent/BE868473A/en not_active IP Right Cessation
- 1978-06-27 FR FR7819207A patent/FR2396082A1/en active Granted
- 1978-06-29 JP JP7972378A patent/JPS5414580A/en active Granted
- 1978-06-29 NL NL7807003A patent/NL7807003A/en not_active Application Discontinuation
- 1978-06-30 IE IE1318/78A patent/IE47062B1/en not_active IP Right Cessation
- 1978-06-30 CH CH718978A patent/CH639694A5/en not_active IP Right Cessation
- 1978-06-30 IT IT25255/78A patent/IT1098354B/en active
- 1978-06-30 HU HU78EI797A patent/HU189441B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA1105859A (en) | 1981-07-28 |
FR2396082B1 (en) | 1980-11-14 |
JPS6141549B2 (en) | 1986-09-16 |
IT7825255A0 (en) | 1978-06-30 |
JPS5414580A (en) | 1979-02-02 |
FR2396082A1 (en) | 1979-01-26 |
GB1602074A (en) | 1981-11-04 |
DE2827963A1 (en) | 1979-01-18 |
CH639694A5 (en) | 1983-11-30 |
HU189441B (en) | 1986-07-28 |
IT1098354B (en) | 1985-09-07 |
IE781318L (en) | 1979-01-01 |
BE868473A (en) | 1978-12-27 |
NL7807003A (en) | 1979-01-03 |
DE2827963C2 (en) | 1987-07-23 |
AR220714A1 (en) | 1980-11-28 |
IL55004A0 (en) | 1978-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4935340A (en) | Method of isolating antibiotic biosynthetic genes | |
US5672497A (en) | Method for increasing the antibiotic-producing ability of antibiotic-producing microorganisms | |
US4513086A (en) | Cloning vectors for use in streptomyces and related organisms | |
US4416994A (en) | Plasmid pEL7 and related cloning vectors for use in streptomyces and related organisms | |
US5190871A (en) | Use of the site-specific integrating function of phage φC31 | |
IE47062B1 (en) | Method of facilitating genetic exchange in streptomyces and nocardia by protoplast fusion | |
US4468462A (en) | Vectors for cloning in streptomyces | |
US4680265A (en) | Method of selecting recombinant DNA-containing streptomyces | |
CA1216249A (en) | Functionally independent cloning vectors for use in streptomyces | |
EP0176321B1 (en) | Recombinant dna cosmid shuttle vectors | |
EP0177228B1 (en) | The use of bacteriophage lambda pl promoter to produce a functional polypeptide in streptomyces | |
US4921801A (en) | Novel recombinant DNA cosmid shuttle vectors | |
US4843002A (en) | Method of selecting recombinant DNA-containing streptomyces | |
US4753880A (en) | Method of selection for spiramycin resistance in streptomyces | |
US4886757A (en) | Spiramycin resistance-conferring cloning vectors | |
EP0238324B1 (en) | Novel plasmid shuttle vectors conferring spiramycin resistance in streptomyces | |
EP0176199B1 (en) | Plasmid phjl210 and related bifunctional cloning vectors for use in streptomycetes | |
US4159226A (en) | Method of obtaining streptomyces protoplasts capable of efficient cell regeneration | |
USRE34875E (en) | Method of selecting recombinant DNA-containing streptomyces |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed |